BioNTech schimba directia - 27 martie 2023 - Revizia istoricului

127.0.0.1: The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

2024-10-31T09:33:49Z

The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

← Versiunea anterioară		Versiunea de la data 31 octombrie 2024 12:33
Linia 1:		Linia 1:

	<p>Venituri totale in 2022: 17.3 mld. EUR, in [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Financial%20Review%20for%20the%20Fourth%20Quarter%20and%20Full%20Year%202022%20Financial%20Results scadere] cu 9% vs anul precedent.</p><p>Profit net in 2022: 9.43 mld. EUR, in [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Financial%20Review%20for%20the%20Fourth%20Quarter%20and%20Full%20Year%202022%20Financial%20Results scadere] cu 8% vs anul precedent.</p><p>EPS in [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Financial%20Review%20for%20the%20Fourth%20Quarter%20and%20Full%20Year%202022%20Financial%20Results 2022]: 37.77 EUR pe actiune (vs 39.63 EUR pe actiune in anul precedent).</p><p>Pentru 2023, BioNTech [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Outlook%20for%20the%202023%20Financial%20Year%3A se asteapta] la venituri totale substantial mai mici, de circa 5 mld. EUR, sub [https://www.biopharma-reporter.com/Article/2023/03/27/BioNTech-s-COVID-19-vaccine-revenue-forecasts-lower-than-expected#:~:text=Lee%20Brown%2C%20global,said%20the%20analyst. asteptarile] analistilor. Cu ocazia publicarii rezultatelor si a estimarilor financiare azi, compania germana [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Outlook%20for%20the%202023%20Financial%20Year%3A a anuntat] ca renegociaza contractul pe care il are cu Comisia Europeana privind furnizarea propriului vaccin anti-Covid, dezvoltat in colaborare cu Pfizer. Discutiile ar putea avea ca rezultat o reducere a vanzarilor imediate, pe seama extinderii livrarilor pe mai multi ani.</p><p>Tot pentru 2023, BioNTech [https://www.reuters.com/business/healthcare-pharmaceuticals/cash-rich-biontech-plans-spend-about-1-bln-more-research-this-year-2023-03-27/#:~:text=In%20a%20statement%20on%20Monday%2C%20Germany%27s%20BioNTech%20(22UAy.DE)%2C%20Pfizer%27s%20(PFE.N)%20partner%20on%20the%20Comirnaty%20vaccine%2C%20said%20it%20plans%20to%20spend%202.4%20to%202.6%20billion%20euros%20on%20research%20and%20development%20(R%26D)%20in%202023%2C%20up%20from%201.54%20billion%20euros%20last%20year. isi propune] sa cheltuiasca pana la 2.6 mld. EUR pentru cercetare si dezvoltare, comparativ cu 1.54 mld. EUR anul trecut. Compania [https://www.theguardian.com/society/2022/oct/16/vaccines-to-treat-cancer-possible-by-2030-say-biontech-founders se reorienteaza] catre dezvoltarea unor tratamente revolutionare contra afectiunilor oncologice, [https://www.reuters.com/business/healthcare-pharmaceuticals/cash-rich-biontech-plans-spend-about-1-bln-more-research-this-year-2023-03-27/#:~:text=It%20will%20also,2023%20and%202024. afirmand] ca, pentru unele dintre acestea, va cere avizul agentiilor de reglementare chiar pe parcursul acestui an si in 2024. La finalul anului 2022, BioNTech [https://www.reuters.com/business/healthcare-pharmaceuticals/cash-rich-biontech-plans-spend-about-1-bln-more-research-this-year-2023-03-27/#:~:text=Thanks%20to%20its%20COVID%2Dvaccine%20market%20lead%20in%20the%20Western%20world%2C%20BioNTech%20ended%20the%20year%202022%20with%20a%20cash%20balance%20of%2013.9%20billion%20euros%20plus%20receivables%2C%20or%20cash%20it%20stands%20to%20receive%2C%20of%207.14%20billion%20euros. avea] lichiditati de 13.9 mld. EUR si creante de 7.14 mld. EUR.</p><p>BioNTech [https://www.reuters.com/business/healthcare-pharmaceuticals/cash-rich-biontech-plans-spend-about-1-bln-more-research-this-year-2023-03-27/#:~:text=The%20company%20said%20it%20expects%20to%20authorise%20new%20share%20buybacks%20worth%20up%20to%20%24500%20million%20this%20year%2C%20having%20already%20spent%20%241.3%20billion%20on%20own%20shares%20through%20March%2017. a mai indicat] azi ca va derula un nou program de buybacks, prin care isi va rascumpa [[actiuni]] proprii in valoare de pana la 500 mil. EUR pana la finalul acestui an. Pana acum, cheltuielile cu buybacks s-au ridicat la 1.3 mld. EUR.</p><p>BioNTech [https://www.reuters.com/article/us-biontech-ipo-idUSKBN1WO29B s-a listat] pe bursa americana, la NASDAQ, in octombrie 2019, la pretul de 10 USD pe actiune. In aceasta dupa-amiaza, compania se tranzactiona la circa 122 USD pe actiune, marcand o pierdere de 28% in ultimele 12 luni.</p><p>(US.BNTX)</p>		<p>Venituri totale in 2022: 17.3 mld. EUR, in [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Financial%20Review%20for%20the%20Fourth%20Quarter%20and%20Full%20Year%202022%20Financial%20Results scadere] cu 9% vs anul precedent.</p><p>Profit net in 2022: 9.43 mld. EUR, in [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Financial%20Review%20for%20the%20Fourth%20Quarter%20and%20Full%20Year%202022%20Financial%20Results scadere] cu 8% vs anul precedent.</p><p>EPS in [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Financial%20Review%20for%20the%20Fourth%20Quarter%20and%20Full%20Year%202022%20Financial%20Results 2022]: 37.77 EUR pe actiune (vs 39.63 EUR pe actiune in anul precedent).</p><p>Pentru 2023, BioNTech [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Outlook%20for%20the%202023%20Financial%20Year%3A se asteapta] la venituri totale substantial mai mici, de circa 5 mld. EUR, sub [https://www.biopharma-reporter.com/Article/2023/03/27/BioNTech-s-COVID-19-vaccine-revenue-forecasts-lower-than-expected#:~:text=Lee%20Brown%2C%20global,said%20the%20analyst. asteptarile] analistilor. Cu ocazia publicarii rezultatelor si a estimarilor financiare azi, compania germana [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Outlook%20for%20the%202023%20Financial%20Year%3A a anuntat] ca renegociaza contractul pe care il are cu Comisia Europeana privind furnizarea propriului vaccin anti-Covid, dezvoltat in colaborare cu [[Pfizer]]. Discutiile ar putea avea ca rezultat o reducere a vanzarilor imediate, pe seama extinderii livrarilor pe mai multi ani.</p><p>Tot pentru 2023, BioNTech [https://www.reuters.com/business/healthcare-pharmaceuticals/cash-rich-biontech-plans-spend-about-1-bln-more-research-this-year-2023-03-27/#:~:text=In%20a%20statement%20on%20Monday%2C%20Germany%27s%20BioNTech%20(22UAy.DE)%2C%20Pfizer%27s%20(PFE.N)%20partner%20on%20the%20Comirnaty%20vaccine%2C%20said%20it%20plans%20to%20spend%202.4%20to%202.6%20billion%20euros%20on%20research%20and%20development%20(R%26D)%20in%202023%2C%20up%20from%201.54%20billion%20euros%20last%20year. isi propune] sa cheltuiasca pana la 2.6 mld. EUR pentru cercetare si dezvoltare, comparativ cu 1.54 mld. EUR anul trecut. Compania [https://www.theguardian.com/society/2022/oct/16/vaccines-to-treat-cancer-possible-by-2030-say-biontech-founders se reorienteaza] catre dezvoltarea unor tratamente revolutionare contra afectiunilor oncologice, [https://www.reuters.com/business/healthcare-pharmaceuticals/cash-rich-biontech-plans-spend-about-1-bln-more-research-this-year-2023-03-27/#:~:text=It%20will%20also,2023%20and%202024. afirmand] ca, pentru unele dintre acestea, va cere avizul agentiilor de reglementare chiar pe parcursul acestui an si in 2024. La finalul anului 2022, BioNTech [https://www.reuters.com/business/healthcare-pharmaceuticals/cash-rich-biontech-plans-spend-about-1-bln-more-research-this-year-2023-03-27/#:~:text=Thanks%20to%20its%20COVID%2Dvaccine%20market%20lead%20in%20the%20Western%20world%2C%20BioNTech%20ended%20the%20year%202022%20with%20a%20cash%20balance%20of%2013.9%20billion%20euros%20plus%20receivables%2C%20or%20cash%20it%20stands%20to%20receive%2C%20of%207.14%20billion%20euros. avea] lichiditati de 13.9 mld. EUR si creante de 7.14 mld. EUR.</p><p>BioNTech [https://www.reuters.com/business/healthcare-pharmaceuticals/cash-rich-biontech-plans-spend-about-1-bln-more-research-this-year-2023-03-27/#:~:text=The%20company%20said%20it%20expects%20to%20authorise%20new%20share%20buybacks%20worth%20up%20to%20%24500%20million%20this%20year%2C%20having%20already%20spent%20%241.3%20billion%20on%20own%20shares%20through%20March%2017. a mai indicat] azi ca va derula un nou program de buybacks, prin care isi va rascumpa [[actiuni]] proprii in valoare de pana la 500 mil. EUR pana la finalul acestui an. Pana acum, cheltuielile cu buybacks s-au ridicat la 1.3 mld. EUR.</p><p>BioNTech [https://www.reuters.com/article/us-biontech-ipo-idUSKBN1WO29B s-a listat] pe bursa americana, la [[Nasdaq\|NASDAQ]], in octombrie 2019, la pretul de 10 USD pe actiune. In aceasta dupa-amiaza, compania se tranzactiona la circa 122 USD pe actiune, marcand o pierdere de 28% in ultimele 12 luni.</p><p>(US.BNTX)</p>
	[[Categorie:US.BNTX]][[Categorie:Analize]][[Categorie:Stiri despre piata]]		[[Categorie:US.BNTX]][[Categorie:Analize]][[Categorie:Stiri despre piata]]
	{{DEFAULTSORT:-2023-03-27}}		{{DEFAULTSORT:-2023-03-27}}

127.0.0.1: The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

2023-09-28T09:22:37Z

The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

← Versiunea anterioară		Versiunea de la data 28 septembrie 2023 12:22
Linia 1:		Linia 1:

	<p>Venituri totale in 2022: 17.3 mld. EUR, in [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Financial%20Review%20for%20the%20Fourth%20Quarter%20and%20Full%20Year%202022%20Financial%20Results scadere] cu 9% vs anul precedent.</p><p>Profit net in 2022: 9.43 mld. EUR, in [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Financial%20Review%20for%20the%20Fourth%20Quarter%20and%20Full%20Year%202022%20Financial%20Results scadere] cu 8% vs anul precedent.</p><p>EPS in [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Financial%20Review%20for%20the%20Fourth%20Quarter%20and%20Full%20Year%202022%20Financial%20Results 2022]: 37.77 EUR pe actiune (vs 39.63 EUR pe actiune in anul precedent).</p><p>Pentru 2023, BioNTech [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Outlook%20for%20the%202023%20Financial%20Year%3A se asteapta] la venituri totale substantial mai mici, de circa 5 mld. EUR, sub [https://www.biopharma-reporter.com/Article/2023/03/27/BioNTech-s-COVID-19-vaccine-revenue-forecasts-lower-than-expected#:~:text=Lee%20Brown%2C%20global,said%20the%20analyst. asteptarile] analistilor. Cu ocazia publicarii rezultatelor si a estimarilor financiare azi, compania germana [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Outlook%20for%20the%202023%20Financial%20Year%3A a anuntat] ca renegociaza contractul pe care il are cu Comisia Europeana privind furnizarea propriului vaccin anti-Covid, dezvoltat in colaborare cu Pfizer. Discutiile ar putea avea ca rezultat o reducere a vanzarilor imediate, pe seama extinderii livrarilor pe mai multi ani.</p><p>Tot pentru 2023, BioNTech [https://www.reuters.com/business/healthcare-pharmaceuticals/cash-rich-biontech-plans-spend-about-1-bln-more-research-this-year-2023-03-27/#:~:text=In%20a%20statement%20on%20Monday%2C%20Germany%27s%20BioNTech%20(22UAy.DE)%2C%20Pfizer%27s%20(PFE.N)%20partner%20on%20the%20Comirnaty%20vaccine%2C%20said%20it%20plans%20to%20spend%202.4%20to%202.6%20billion%20euros%20on%20research%20and%20development%20(R%26D)%20in%202023%2C%20up%20from%201.54%20billion%20euros%20last%20year. isi propune] sa cheltuiasca pana la 2.6 mld. EUR pentru cercetare si dezvoltare, comparativ cu 1.54 mld. EUR anul trecut. Compania [https://www.theguardian.com/society/2022/oct/16/vaccines-to-treat-cancer-possible-by-2030-say-biontech-founders se reorienteaza] catre dezvoltarea unor tratamente revolutionare contra afectiunilor oncologice, [https://www.reuters.com/business/healthcare-pharmaceuticals/cash-rich-biontech-plans-spend-about-1-bln-more-research-this-year-2023-03-27/#:~:text=It%20will%20also,2023%20and%202024. afirmand] ca, pentru unele dintre acestea, va cere avizul agentiilor de reglementare chiar pe parcursul acestui an si in 2024. La finalul anului 2022, BioNTech [https://www.reuters.com/business/healthcare-pharmaceuticals/cash-rich-biontech-plans-spend-about-1-bln-more-research-this-year-2023-03-27/#:~:text=Thanks%20to%20its%20COVID%2Dvaccine%20market%20lead%20in%20the%20Western%20world%2C%20BioNTech%20ended%20the%20year%202022%20with%20a%20cash%20balance%20of%2013.9%20billion%20euros%20plus%20receivables%2C%20or%20cash%20it%20stands%20to%20receive%2C%20of%207.14%20billion%20euros. avea] lichiditati de 13.9 mld. EUR si creante de 7.14 mld. EUR.</p><p>BioNTech [https://www.reuters.com/business/healthcare-pharmaceuticals/cash-rich-biontech-plans-spend-about-1-bln-more-research-this-year-2023-03-27/#:~:text=The%20company%20said%20it%20expects%20to%20authorise%20new%20share%20buybacks%20worth%20up%20to%20%24500%20million%20this%20year%2C%20having%20already%20spent%20%241.3%20billion%20on%20own%20shares%20through%20March%2017. a mai indicat] azi ca va derula un nou program de buybacks, prin care isi va rascumpa actiuni proprii in valoare de pana la 500 mil. EUR pana la finalul acestui an. Pana acum, cheltuielile cu buybacks s-au ridicat la 1.3 mld. EUR.</p><p>BioNTech [https://www.reuters.com/article/us-biontech-ipo-idUSKBN1WO29B s-a listat] pe bursa americana, la NASDAQ, in octombrie 2019, la pretul de 10 USD pe actiune. In aceasta dupa-amiaza, compania se tranzactiona la circa 122 USD pe actiune, marcand o pierdere de 28% in ultimele 12 luni.</p><p>(US.BNTX)</p>		<p>Venituri totale in 2022: 17.3 mld. EUR, in [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Financial%20Review%20for%20the%20Fourth%20Quarter%20and%20Full%20Year%202022%20Financial%20Results scadere] cu 9% vs anul precedent.</p><p>Profit net in 2022: 9.43 mld. EUR, in [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Financial%20Review%20for%20the%20Fourth%20Quarter%20and%20Full%20Year%202022%20Financial%20Results scadere] cu 8% vs anul precedent.</p><p>EPS in [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Financial%20Review%20for%20the%20Fourth%20Quarter%20and%20Full%20Year%202022%20Financial%20Results 2022]: 37.77 EUR pe actiune (vs 39.63 EUR pe actiune in anul precedent).</p><p>Pentru 2023, BioNTech [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Outlook%20for%20the%202023%20Financial%20Year%3A se asteapta] la venituri totale substantial mai mici, de circa 5 mld. EUR, sub [https://www.biopharma-reporter.com/Article/2023/03/27/BioNTech-s-COVID-19-vaccine-revenue-forecasts-lower-than-expected#:~:text=Lee%20Brown%2C%20global,said%20the%20analyst. asteptarile] analistilor. Cu ocazia publicarii rezultatelor si a estimarilor financiare azi, compania germana [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Outlook%20for%20the%202023%20Financial%20Year%3A a anuntat] ca renegociaza contractul pe care il are cu Comisia Europeana privind furnizarea propriului vaccin anti-Covid, dezvoltat in colaborare cu Pfizer. Discutiile ar putea avea ca rezultat o reducere a vanzarilor imediate, pe seama extinderii livrarilor pe mai multi ani.</p><p>Tot pentru 2023, BioNTech [https://www.reuters.com/business/healthcare-pharmaceuticals/cash-rich-biontech-plans-spend-about-1-bln-more-research-this-year-2023-03-27/#:~:text=In%20a%20statement%20on%20Monday%2C%20Germany%27s%20BioNTech%20(22UAy.DE)%2C%20Pfizer%27s%20(PFE.N)%20partner%20on%20the%20Comirnaty%20vaccine%2C%20said%20it%20plans%20to%20spend%202.4%20to%202.6%20billion%20euros%20on%20research%20and%20development%20(R%26D)%20in%202023%2C%20up%20from%201.54%20billion%20euros%20last%20year. isi propune] sa cheltuiasca pana la 2.6 mld. EUR pentru cercetare si dezvoltare, comparativ cu 1.54 mld. EUR anul trecut. Compania [https://www.theguardian.com/society/2022/oct/16/vaccines-to-treat-cancer-possible-by-2030-say-biontech-founders se reorienteaza] catre dezvoltarea unor tratamente revolutionare contra afectiunilor oncologice, [https://www.reuters.com/business/healthcare-pharmaceuticals/cash-rich-biontech-plans-spend-about-1-bln-more-research-this-year-2023-03-27/#:~:text=It%20will%20also,2023%20and%202024. afirmand] ca, pentru unele dintre acestea, va cere avizul agentiilor de reglementare chiar pe parcursul acestui an si in 2024. La finalul anului 2022, BioNTech [https://www.reuters.com/business/healthcare-pharmaceuticals/cash-rich-biontech-plans-spend-about-1-bln-more-research-this-year-2023-03-27/#:~:text=Thanks%20to%20its%20COVID%2Dvaccine%20market%20lead%20in%20the%20Western%20world%2C%20BioNTech%20ended%20the%20year%202022%20with%20a%20cash%20balance%20of%2013.9%20billion%20euros%20plus%20receivables%2C%20or%20cash%20it%20stands%20to%20receive%2C%20of%207.14%20billion%20euros. avea] lichiditati de 13.9 mld. EUR si creante de 7.14 mld. EUR.</p><p>BioNTech [https://www.reuters.com/business/healthcare-pharmaceuticals/cash-rich-biontech-plans-spend-about-1-bln-more-research-this-year-2023-03-27/#:~:text=The%20company%20said%20it%20expects%20to%20authorise%20new%20share%20buybacks%20worth%20up%20to%20%24500%20million%20this%20year%2C%20having%20already%20spent%20%241.3%20billion%20on%20own%20shares%20through%20March%2017. a mai indicat] azi ca va derula un nou program de buybacks, prin care isi va rascumpa [[actiuni]] proprii in valoare de pana la 500 mil. EUR pana la finalul acestui an. Pana acum, cheltuielile cu buybacks s-au ridicat la 1.3 mld. EUR.</p><p>BioNTech [https://www.reuters.com/article/us-biontech-ipo-idUSKBN1WO29B s-a listat] pe bursa americana, la NASDAQ, in octombrie 2019, la pretul de 10 USD pe actiune. In aceasta dupa-amiaza, compania se tranzactiona la circa 122 USD pe actiune, marcand o pierdere de 28% in ultimele 12 luni.</p><p>(US.BNTX)</p>
	[[Categorie:US.BNTX]][[Categorie:Analize]][[Categorie:Stiri despre piata]]		[[Categorie:US.BNTX]][[Categorie:Analize]][[Categorie:Stiri despre piata]]
	{{DEFAULTSORT:-2023-03-27}}		{{DEFAULTSORT:-2023-03-27}}

Admin: csv2wiki

2023-04-21T16:19:21Z

csv2wiki

Pagină nouă

Venituri totale in 2022: 17.3 mld. EUR, in [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Financial%20Review%20for%20the%20Fourth%20Quarter%20and%20Full%20Year%202022%20Financial%20Results scadere] cu 9% vs anul precedent.Profit net in 2022: 9.43 mld. EUR, in [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Financial%20Review%20for%20the%20Fourth%20Quarter%20and%20Full%20Year%202022%20Financial%20Results scadere] cu 8% vs anul precedent.EPS in [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Financial%20Review%20for%20the%20Fourth%20Quarter%20and%20Full%20Year%202022%20Financial%20Results 2022]: 37.77 EUR pe actiune (vs 39.63 EUR pe actiune in anul precedent).Pentru 2023, BioNTech [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Outlook%20for%20the%202023%20Financial%20Year%3A se asteapta] la venituri totale substantial mai mici, de circa 5 mld. EUR, sub [https://www.biopharma-reporter.com/Article/2023/03/27/BioNTech-s-COVID-19-vaccine-revenue-forecasts-lower-than-expected#:~:text=Lee%20Brown%2C%20global,said%20the%20analyst. asteptarile] analistilor. Cu ocazia publicarii rezultatelor si a estimarilor financiare azi, compania germana [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Outlook%20for%20the%202023%20Financial%20Year%3A a anuntat] ca renegociaza contractul pe care il are cu Comisia Europeana privind furnizarea propriului vaccin anti-Covid, dezvoltat in colaborare cu Pfizer. Discutiile ar putea avea ca rezultat o reducere a vanzarilor imediate, pe seama extinderii livrarilor pe mai multi ani.Tot pentru 2023, BioNTech [https://www.reuters.com/business/healthcare-pharmaceuticals/cash-rich-biontech-plans-spend-about-1-bln-more-research-this-year-2023-03-27/#:~:text=In%20a%20statement%20on%20Monday%2C%20Germany%27s%20BioNTech%20(22UAy.DE)%2C%20Pfizer%27s%20(PFE.N)%20partner%20on%20the%20Comirnaty%20vaccine%2C%20said%20it%20plans%20to%20spend%202.4%20to%202.6%20billion%20euros%20on%20research%20and%20development%20(R%26D)%20in%202023%2C%20up%20from%201.54%20billion%20euros%20last%20year. isi propune] sa cheltuiasca pana la 2.6 mld. EUR pentru cercetare si dezvoltare, comparativ cu 1.54 mld. EUR anul trecut. Compania [https://www.theguardian.com/society/2022/oct/16/vaccines-to-treat-cancer-possible-by-2030-say-biontech-founders se reorienteaza] catre dezvoltarea unor tratamente revolutionare contra afectiunilor oncologice, [https://www.reuters.com/business/healthcare-pharmaceuticals/cash-rich-biontech-plans-spend-about-1-bln-more-research-this-year-2023-03-27/#:~:text=It%20will%20also,2023%20and%202024. afirmand] ca, pentru unele dintre acestea, va cere avizul agentiilor de reglementare chiar pe parcursul acestui an si in 2024. La finalul anului 2022, BioNTech [https://www.reuters.com/business/healthcare-pharmaceuticals/cash-rich-biontech-plans-spend-about-1-bln-more-research-this-year-2023-03-27/#:~:text=Thanks%20to%20its%20COVID%2Dvaccine%20market%20lead%20in%20the%20Western%20world%2C%20BioNTech%20ended%20the%20year%202022%20with%20a%20cash%20balance%20of%2013.9%20billion%20euros%20plus%20receivables%2C%20or%20cash%20it%20stands%20to%20receive%2C%20of%207.14%20billion%20euros. avea] lichiditati de 13.9 mld. EUR si creante de 7.14 mld. EUR.BioNTech [https://www.reuters.com/business/healthcare-pharmaceuticals/cash-rich-biontech-plans-spend-about-1-bln-more-research-this-year-2023-03-27/#:~:text=The%20company%20said%20it%20expects%20to%20authorise%20new%20share%20buybacks%20worth%20up%20to%20%24500%20million%20this%20year%2C%20having%20already%20spent%20%241.3%20billion%20on%20own%20shares%20through%20March%2017. a mai indicat] azi ca va derula un nou program de buybacks, prin care isi va rascumpa actiuni proprii in valoare de pana la 500 mil. EUR pana la finalul acestui an. Pana acum, cheltuielile cu buybacks s-au ridicat la 1.3 mld. EUR.BioNTech [https://www.reuters.com/article/us-biontech-ipo-idUSKBN1WO29B s-a listat] pe bursa americana, la NASDAQ, in octombrie 2019, la pretul de 10 USD pe actiune. In aceasta dupa-amiaza, compania se tranzactiona la circa 122 USD pe actiune, marcand o pierdere de 28% in ultimele 12 luni.(US.BNTX)
[[Categorie:US.BNTX]][[Categorie:Analize]][[Categorie:Stiri despre piata]]
{{DEFAULTSORT:-2023-03-27}}